Tear proteomics has revealed a reproducible inflammatory and immune signature in lacrimal drainage disorders, positioning tear fluid as a valuable, noninvasive biospecimen for diagnosis, monitoring, and precision-based management. Emerging biomarker panels hold potential to stratify disease severity, predict surgical success, and guide individualized therapy. Future work should prioritize multicenter validation, standardized sampling protocols, and integration with advanced analytical and AI-driven diagnostic platforms.
Shams et al. (Sat,) studied this question.